High versus standard adalimumab induction dosing regimens in patients with moderately to severely active Crohn's disease: Results from the SERENE-CD induction study

(1) Amsterdam University Medical Centers,Amsterdam,Netherlands

(2) University of California San Diego,San Diego,United States

(3) Mayo Clinic,Rochester,United States

(4) Feinberg School of Medicine, Northwestern University,Chicago,United States

(5) University Hospital Schleswig-Holstein,Kiel,Germany

(6) Nancy University Hospital Inserm U954 Dept. of Hepato-Gastroenterology,Vandoeuvre les Nancy,France

(7) University of Calgary,Calgary,Canada

(8) Hospital Clínic Barcelona Dept. of Gastroenterology - Dept. of Gastroenterology, Hospital Clínic Bar,Barcelona,Spain

(9) Icahn School of Medicine at Mount Sinai,USA,United States

(10) University Hospitals Leuven,Leuven,Belgium

(11) University Hospital of Liège,Liège,Belgium

(12) Fondazione Policlinico Universitario A. Gemelli IRCCS,Rome,Italy

(13) AbbVie Inc,North Chicago,United States

(14) Humanitas Research Hospital,Rozzano,Italy



This item was part of the Late breaking abstracts: IBD Highlights session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019